This update will illuminate why TRXC will likely continue having a major share price correction in the near term. TRXC has ties to Phil Frost who was recently charged by the SEC with orchestrating many microcap pump and dumps (more on this below). In addition, TRXC has a history of its stock price running up, and each time, insiders top-tick the stock - we'll show you how this time is no different. After speaking to various robotic surgery experts, we believe that the Senhance has several significant fundamental flaws that will prevent widespread adoption. This is why the TRXC story will end with investors in tears.
For those who have followed the story from the beginning, it has been well documented that TRXC's history was littered with stock promotion. On 2/1/16, Broad Street Alerts published a report on speculation that Johnson & Johnson (JNJ) was considering acquiring TRXC. Broad Street Alerts is a newsletter that promotes small cap stocks to retail investors.
What investors may not know is that the company's roots have deep ties to Dr. Phillip Frost, who was recently charged by the SEC with numerous microcap pump and dump schemes. TRXC came public via a reverse merger with SafeStitch Medical. Frost was a major shareholder and investor in SafeStitch, and Jane Hsiao (current TRXC director) was chair of the company at the time of the reverse takeover. They invested together in SafeStitch with their oddly similarly named investment entities: Frost Gamma Investments Trust (Dr. Frost) and Hsu Gamma Investment, L.P. (Hsiao). Notably, Hsiao is on the board of Cocrystal Pharma (COCP - formerly Biozone), one of the companies identified in the SEC lawsuit. The SEC charged Dr. Frost and his associates with selling unprofitable assets to COCP, using financing to amass cheap shares, and orchestrating a pump-and-dump for personal gain.
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year. These returns cover a period from January 1, 1988 through February 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Add some conviction to your trading! We sort through +4,000 ETFs/CEFs along with +16,000 U.S. stocks/ADRs to find the best trade ideas. Click here for a two-week free trial and explore our content at the Conviction Dossier.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
The following securities have additional requirements in place, and we will not be extending margin credit on some trading strategies. This is part of our normal course of business in situations of unusual volatility. You may continue to place buy and sell stock orders.
For clients interested in trading non-exchange-traded, Over The Counter (OTC) stocks, the industry is currently experiencing unusually high trading volume and third-party market makers currently may be delayed or in certain limited circumstances unable to complete trades in certain OTC stocks. Some market makers may reject unmarketable sell limit orders with a limit price far away from the stock price.
Asensus Surgical (NYSEAMERICAN:ASXC) (until recently known as TransEnterix) is a small biotech company seeking to commercialize surgical devices. ASXC stock has gone on a rocky ride over the past few years.
If you owned TRXC stock for more than a few months, you know this company has a long and underwhelming track record. In general, you should be wary of companies that reverse split their stocks, change their names and ticker symbols, and fail to produce meaningful revenues or profits for many years at a time.
These 6 additional grades for each stock are a compliment to the overall POWR Rating shown to the left. Investors should first focus their research on stocks with an overall Buy rating of A or B. Then, and only then, use the component grades to drill down to the stocks that meet your unique investing style. In general, the more component grades of A or B the better the odds that the stock should outperform.
AMEX stock TRXC Transenterix Inc forecast & share price targets are below. These share price targets & forecast are valid from short-term to mid-term to long-term. If you just want tomorrow's movements predictions for Transenterix Inc then click here or Transenterix Inc share price targets or view what Experts say about Transenterix Inc or Announcements & NEWS by Transenterix Inc
The stock price is currently trading at 4.08
However, if the trend reverses from this point, then possible future share price targets could be 4, 3, 2, 1, or even 0.20
These share price targets are working as long-term support & resistance levels as well.
38c6e68cf9